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ABSTRACT 
 
Introduction 
Effective medical expulsion for ureteric stones with α-blockers offers numerous 
advantages over surgical alternatives. However, its effectiveness remains uncertain 
and with the publication of new trial data, the available evidence requires 
reappraisal.  
 
Objective 
To assess the efficacy of α-blockers the management of ureteric lithiasis. 
 
Methods 
A systematic review of the literature, with pre-defined search criteria, was conducted 
using Pubmed and Embase. All randomised trials comparing α-blocker monotherapy 
to placebo or standard therapy were included. Stone expulsion rate was the primary 
outcome measure. Secondary outcome measures were time to stone expulsion, 
analgesic usage and pain scores. Subgroup analyses assessed individual 
adrenergic antagonists and variations in standard therapy. Sensitivity analysis was 
based on stone location, stone size, Cochrane Risk of Bias score and study protocol. 
Summary effects were calculated using a random-effects model and presented as 
Relative risks (RR) and mean differences (MD) for dichotomous and continuous 
outcome measures respectively.  
 
 
Results 
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67 studies randomising 6654 patients were included in the meta-analysis. Stone 
expulsion rates improved with α-blockers (RR, 1.49; 95% CI 1.38-1.61). Contrast 
enhanced funnel showed evidence of publication bias. Stone expulsion time was 
3.99 days (CI -4.75- -3.23) shorter with α-blockers. Similarly, patients required 
106.53mg [CI -148.20- -64.86] less diclofenac compared to control/placebo, and had 
0.80 [CI -1.07 – -0.54] fewer pain episodes. Visual Analogue Scores were also 
reduced, -2.43 [CI -3.87 – -0.99]. All formulations of α-antagonists all demonstrated 
beneficial effects over conservative treatment/placebo. Sensitivity analysis 
demonstrated significant effects of stone location, stone size and study design. 
 
Conclusions and Relevance 
Despite the opposing results of recently published trial, current evidence continues to 
demonstrate a potential benefit of α-blocker treatment particularly for distal stones 
over 5mm.  
 
How did you gather, select and analyze the info you considered in your 
review?'  
Online databases (Medline, Embase) where searched for all studies including 
abstracts. Clinical trials databases were searched for emerging and unpublished 
studies. All trials that compared stone expulsion rates in α-blockers and standard 
therapy or placebo were included in the analysis. 
 
Take-home message for the clinician?  
Despite the recent publication of major trials with conflicting results, the results of this 
meta-analysis continue to support the beneficial role of α-blockers in the 
management ureteric calculi. 
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INTRODUCTION 
 
Urolithiasis remains a common complaint in an often otherwise healthy population. 
With a prevalence of 2-3% and recurrence rates of up to 50%, the morbidity of 
urolithiasis is clearly reflected in the volume of literature evaluating its management 
and treatment.  
 
Whilst some stones may remain asymptomatic, an obstructing ureteric calculus with 
infection represents a surgical emergency requiring immediate intervention. Pain is 
the main cause for hospital admissions and the likelihood of stone passage is key to 
determining further management. Smaller stones are liable to pass spontaneously 
with stones less than 5mm having a 68% chance of passing without treatment.[1] As 
stone sizes increases, spontaneous passage rates diminish and consequently the 
need for active treatment increases. Surgical options such as lithotripsy and 
ureteroscopy offer high stone free rates but at price both in terms of increased costs 
to the health system and increased risk to the patient. Effective medial expulsive 
treatment aims to bridge this gap with the potential for treatment of ureteric stone 
diseased without the risks or costs of surgical interventions.  
 
By inhibiting the contraction of ureteric smooth muscle, α-blockers are believed to 
promote antegrade stone passage and reduce colic. A large number of randomised 
studies have been performed assessing their efficacy. Up till now the results from the 
majority of meta analyses have shown a benefit of alpha blocker treatment in 
increasing stone expulsion rates and times.[1-6] Medical expulsive therapy is now 
widely prescribed yet the evidence remains hotly debated[7]. In response the 
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SUSPEND trial, a large multicentre randomised trial, was conducted assessing the 
effectiveness of tamsulosin, nifedipine and placebo in treating ureteric calculi. 
 
We have performed the first meta-analysis incorporating these new findings into the 
existing body of literature to assess the value of α-blockers in treating ureteric 
calculi.  
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METHODS 
This study was performed using the guidelines set out by the Preferred Reporting 
Items for Systematic reviews and Meta-Analysis (PRISMA) statement. PROSPERO 
registration number: CRD42015029499. 
 
Search Strategy  
Searches of electronic databases (Pubmed, Embase) were performed to identify 
relevant full texts and abstracts. Clinical trial registries (ClinicalTrials.gov; 
International Clinical Trials Register) were searched for unpublished and emerging 
trials and authors were contacted for results. Searches were completed on 20th 
February 2016. No time restrictions were placed on search results. The following 
MeSH terms and keywords were used in various combinations; “urolithiasis”, “alpha 
blocker”, “tamsulosin”, “alfuzosin”, “medical expulsive therapy”, “silodosin”, 
“terazosin”, “doxazosin”, “calculus”, “stone”, “ureteric” “renal colic”, “ureter* colic”, 
“expulsive therapy”, “facilitated passage”. See supplementary table 1 for the search 
strategy. Reference lists were searched by hand for further eligible studies. 
 
Inclusion Criteria 
All English language studies published up to 20th February 2016 were included if 
they met the following criteria: 
 
1. Patients presenting with acute ureteric colic 
2. Adult patients >18 years 
3. Single ureteric calculus 
4. A-blocker monotherapy compared to placebo/ standard therapy 
5. Prospective, randomised studies 
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Exclusion Criteria 
Studies were excluded if any of the following criteria were met. 
1. Studies without original data  
2. Studies in which α-blockers were used as adjuvants to lithotripsy or surgery 
3. Studies that did not report stone free rates 
4. Animal studies 
 
Quality Assessment 
All studies were evaluated using The Cochrane Collaboration’s tool for assessing 
risk of bias[8]. Trials were categorised into low, intermediate and high risk groups. 
 
Data Review and Analysis 
A standardised data extraction form was agreed prior to the literature searches being 
performed. Two reviewers independently extracted data using the standardised form. 
Extracted information included baseline study characteristics (single/multi centre; 
randomisation method; blinding; power calculation and sample size), number of 
enrolled patients and drop outs; analysis technique (per protocol/ intention to treat), 
inclusion/ exclusion criteria, baseline patient characteristics (age, sex), size of stone, 
position of stone, diagnosis technique, follow up protocol and duration, treatment 
regime, expulsion rate and time, symptoms, analgesic requirements, adverse effects 
and withdrawals. Authors of studies for which additional information was required 
were contacted by email. 
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Primary analysis compared the rate of stone expulsion in patients receiving standard 
dose α-blockers to standard therapy or placebo. Standard therapy was defined as 
symptomatic management regimes including fluids, analgesia, anti-cholinergic 
agents, anti-spasmodic agents and steroids given to both intervention and control 
arms. 
 
Secondary analysis compared time to stone expulsion, analgesic usage and pain 
score variations. 
 
Subgroup analyses, identified a priori, assessed placebo-controlled trials, individual 
adrenergic antagonists and variations in standard therapy regimes. Unless otherwise 
stated, all analyses compared α-blockers against conservative treatment/placebo. 
Sensitivity analysis was performed based on the Cochrane risk of bias score for 
each study, trial analysis protocol, stone position and stone size. 
 
STATISTICAL METHODS 
 
For dichotomous variables Mantel-Haenszel test pooled risk ratios (RR) were used 
to evaluate the relative benefit of α-blocker treatment. For continuous variables 
inverse variance weighted mean differences were calculated. Given the 
heterogeneity a random effects model was used for both continuous and 
dichotomous variables. Forest plots were created to display the RR estimates for 
each study. Potential heterogeneity was assessed using the I2 statistic and “remove-
one” analysis. Publication bias was assessed for by visual inspection of the contrast 
enhanced funnel plot[9]. Evidence of small study effects was further evaluated using 
Peter’s test[10]. To further identify possible sources of significant heterogeneity 
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sensitivity analysis was performed. Analyses were performed using Revman v. 5.3 
(Copenhagen: The Nordic Centre, The Cochrane Collaboration) and Stata software 
v. 14 (Stata Corp, College Station, TX). 
 
RESULTS 
 
The initial search for randomised studies assessing the efficacy of α-blockers 
resulted in 1184 articles via Medline and Embase. After review of the abstracts, 127 
articles were selected for more detailed review. 15 further studies were identified 
through hand searches of bibliographies. On the criteria detailed above, we excluded 
14 studies. Figure 1 provides details of the excluded studies. Finally, 67 studies 
randomising 6654 patients were selected for inclusion into the meta-analysis (Table 
1).   
 
Primary Outcome Analysis 
 
Primary analysis compared α-blocker therapy to standard conservative treatment/ 
placebo. Random effects analysis assessing the chance of passing a ureteric 
calculus indicated a RR of 1.49 (95% CI 1.38-1.61) in favour of α-blockers (Figure 2). 
The I2 statistic showed significant heterogeneity (I2 = 75%). Remove-one analysis did 
not demonstrate a major influence of one particular study. Neither the pooled RR nor 
I2 changed significantly with removal of any one study (results not shown).  Contour 
enhanced funnel plot demonstrates significant asymmetry. An absence of studies in 
the area of low significance suggests a degree of publication bias which was 
confirmed by Peter’s test(P<0.05) (Figure 3). Adjustment of the funnel plot using trim 
and fill suggested 21 missing studies however these led to only a modest change in 
outcomes (Supplementary Figure 1). Analysis of estimated effect of this publication 
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bias showed that whilst pooled RR was reduced to 1.31 (95% CI 1.22 to 1.41), the 
effects remained significant. 
 
Quality Assessment 
 
Results of quality assessment using the Cochrane Risk of Bias tool can be found in 
Figure 7. Overall a high degree of bias was seen with only nine studies judged to be 
at low risk[11-19]  whilst 41 were judged to be intermediate risk[20-60] and 17 high 
risk[61-77]. The most common cause for bias was blinding of both participants and 
personnel and outcomes assessment.  
 
 
Secondary Outcome Analysis 
 
The key secondary outcome measure is stone expulsion time. Analysis of 31 
studies, 2433 subjects, showed reduced expulsion time with α-blocker therapy by 
3.99 days [CI -4.75 - -3.23] compared to standard therapy or control (I2=88%, 
p=<0.00001) (Figure 4). 
 
Functional outcomes such as analgesic usage and pain scores were poorly reported 
by the majority of studies preventing comprehensive analysis. Diclofenac 
requirements were reported by 13 studies with 909 
participants[12,24,25,30,32,37,40,48,52,57,58,66,67]. Alpha-blockers treatment 
resulted in patients using 106.53mg less diclofenac [CI -148.20 - -64.86] compared 
to standard therapy/placebo (I2=99%, p<0·00001).14 studies reported the number of 
pain episodes experienced within α-blockers and control/placebo 
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cohorts[12,17,19,24,51,52,57-60,66-68,76]. Α-blockers resulted in 0.80 [CI -1.07 – -
0.54] fewer pain episodes as compared to control (I2=81%, p<0.00001). Just six 
studies, 1130 participants, reported Visual Analogue Scores to pain 
measurement[16,24,46,51,56,66]. A mean score difference of -2.43 was seen with α-
blockers [CI -3.87 – -0.99] (I2=97%, p<0.00001). 12 studies, 1524 patients, reported 
side-effects experienced [12,16,21,25,29,48,51,59,65,67,68,76]. Α-blockers 
treatment resulted in a RR of 1.59 [CI 1.01– 2.51] (I2=0%, p=0·80). 
 
Subgroup analysis all demonstrated similarly beneficial effects to α-blockers 
treatment. 16 studies of 2633 patients compared α-blockers to placebo[11-16,18-
21,32,44,47,64,69,73], RR = 1.28 [CI 1.13-1.44], I2=81%, p=<0·00001). Confining 
analysis to just tamsulosin, 48 studies compared it to standard therapy or placebo. 
Outcomes were very similar to the primary analysis with RR 1·48 [CI 1.35-1.62] in 
favour of α-blockers (I2=77%, p=<0.00001).  Further studies analysed the individual 
effects of terazosin, doxazosin, alfuzosin and silodosin. In all cases, treatment with 
an α-blocker resulted in increased stone expulsion rates (Supplementary Figure 2). 
Various regimes constituted standard therapy across the 68 studies. Three studies 
prescribed patients only fluids. 35 studies gave fluids and analgesia and 221 studies 
gave only analgesia. Seven studies gave all patients anticholinergic medications 
routinely whilst one study did not stipulate a standard therapy regime[16]. Aside from 
the three studies that advised fluids alone which demonstrated an equivocal 
collective outcome, α-blockers were associated with increased stone expansion 
across all management regimes (Supplementary Figure 3). 
 
Sensitivity analysis was performed to assess for possible sources of heterogeneity. 
 13 
The effect of bias was explored through comparison of low, intermediate and high 
risk studies (Figure 7). The nine low risk trials demonstrated a modest but significant 
benefit of α-blocker therapy (RR 1.15 (CI 1.02- 1.30; I2 = 77% p=<0.0001). Studies 
with an intermediate (n=41) or high risk of bias (n=17) showed greater beneficial 
effects of alpha blockers (intermediate risk RR= 1.52 [CI 1.42-1.62] I2= 34% p=0.02; 
high risk RR= 1.60 [CI 1.35-1.91], I2= 65%, p= 0.0001) (Supplementary Figure 4). 
The differences between low risk and intermediate risk and low risk and high risk 
were significant (ratio of relative risk (RRR)= 0.76 [CI 0.66-0.87] and RRR= 0.72 [CI 
0.58-0.88] respectively)[78].  
 
 
Stone location was used to further evaluate the robustness of the data set. The 
authors’ definition of distal, mid and proximal ureteric calculi was followed. The 
majority of studies included only distal ureteric stones however 10 included proximal 
stones and four studies included mid ureteric stones. Six studies did not report stone 
position[35,40,47,72,74,79]. Whilst beneficial in distal and proximal stones, α-
blockers were more significantly more effective in treating distal ureteric stones (RR= 
1.50 [CI 1.38- 1.62], I2= 51% p= <0.00001). Effects did not reach significance in mid 
ureteric stones likely due to the small number of studies included (Supplementary 
Figure 5). 
 
60 studies reported mean stone size. Stratified by stone size (less or equal to 5mm 
vs greater than 5mm) both groups showed a higher stone free rate with alpha-
blockers vs standard therapy/control (stone ≤ 5mm: RR 1.19 [CI 1.08-1.31], I2=55% 
p=0.004; stone > 5mm: RR 1.60 [CI 1.44-1.77] I2=72%, p<0.00001). As expected, 
the benefit of α-blocker treatment increased with greater stone diameter (Figure 5). 
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Sensitivity analysis was also performed on non-adherence to study protocol.  Seven 
studies applied intention to treat analysis[18,33,43,48,58,62,65]. Data for remaining 
studies, which used either per protocol analysis or did not state an analysis method, 
were then reassessed using an intention to treat protocol. Primary outcome analysis 
was largely unaffected (RR= 1.51 [CI= 1.39 -1.65] I2= 76% p< 0.00001).  
 
DISCUSSION 
 
The pooled results of 67 randomised trials involving 6654 participants suggests that 
overall α-blockers significantly increase the rate of ureteric stone passage. Use of an 
α-blocker is associated with a 40% increase in the chance of passing a ureteric 
stone compared to either standard therapy or placebo. Tamsulosin was used in the 
majority of studies however all formulations (tamsulosin, doxazosin, terazosin, 
alfuzosin, silodosin, naftopidil) demonstrated beneficial effects of α-antagonism in 
stone expulsion. In addition to an increased rate of stone expulsion, α-blockers were 
associated with a shorter time to stone expulsion.  
 
Variations in outcome measures and study methodologies impeded assessment of 
secondary outcomes such as pain, analgesic use and side effects. Only nine studies 
reported diclofenac usage and 11 studies reported pain scores, both of which 
showed reduce pain with α blocker usage. Conversely, whilst it is acknowledged that 
side affects are generally poorly reported, a small increased event rate of side 
effects was seen with α-blockers. Yet treatment appears to be well tolerated. Across 
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all studies only 21 patients were reported to have withdrawn because of adverse 
effects.  
 
Significant heterogeneity was demonstrated on analysis. Both the contrast enhanced 
funnel plot and Peter’s test provided evidence for publication bias.  
 
Yet the effects of bias were shown to be more limited and when adjusted for bias, 
the results remained significant. As seen in previous analysis, whilst publication bias 
remains fairly prevalent, its impact on outcomes appears to be far more limited[80]. 
Sensitivity analysis for potential factors of clinical factors proved to be similarly 
insignificant. In contrast to protocol deviations which did not significantly affect 
outcomes, an association was seen with overall study quality. Nonetheless even 
when limited to high quality studies, the beneficial effects of α-blockers remained 
significant. Stone position and size were also significant factors. A-blockers were 
significantly more effective in treating stones larger than 5mm with a 38% greater 
chance of stone passage, likely due to the high spontaneous passage rate of small 
stones[1]. Stone location influenced treatment efficacy as well. Whereas distal 
stones were 51% more likely to pass with α-blockers, treatment was ineffective for 
mid and proximal ureteric stones. Α-antagonists target the action of α-
adrenoreceptors in ureteral smooth muscle. Most abundant subtypes are 1-a and 1-d 
particularly in the distal ureter where α-blockers will be most effective. In vitro studies 
have shown both that α-adrenoceptor stimulation promotes peristaltic activity while 
antagonism reduces ureteric tone[81-83]. Smooth muscle relaxation leads to 
reduced intraureteral pressure increasing urine flow above the stone whilst reducing 
pressure distally. The net increase in the intraureteral pressure gradient results in a 
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greater expulsive force[84,85]. Inhibition of peristalsis reduces the painful colic 
associated with stone passage. 
 
In line with previous reviews, this meta-analysis continues to demonstrate a 
beneficial effect of α-blockers in treating ureterolithiasis[2-6]. These results contrast 
with the multicentre SUSPEND trial by Pickard et al that did not show a benefit of α-
blocker treatment[16]. Variations in clinical factors and study design were found to 
have significant effects on trial outcomes but these did not affect the review’s primary 
outcome. 
 
Whilst the SUSPEND trial’s methodology is in many respects very robust, certain 
aspects do require further consideration. Although the study included stones less 
than 10mm, the majority of patients had stones less than 5mm, which have a high 
chance of passing spontaneously[1]. Subgroup analysis of 282 patients (24.8%) with 
larger stones (>5mm) was performed showing a trend towards the benefit of 
tamsulosin over placebo (71.3% vs 60.6%). This did not reach significance but small 
patient numbers may mean this subgroup analysis was underpowered. Similarly, for 
stone position a greater but not significant benefit was seen with distal ureteric 
stones. In contrast our findings for stones over 5mm, based on 3850 patients, 
demonstrated a significant benefit with α-blockers. Secondly whilst the pragmatic 
end point of a need for intervention is arguably more useful to the clinician in the 
field, it is a more imprecise assessment of stone passage rates compared to 
radiological assessment as used in the majority of studies. Together with a lack of 
data on compliance rates, there is the potential for under recording stone passages 
rates especially in the smaller >5mm patient group.  
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Conclusion 
 
Despite the results of the SUSPEND trial, α-blocker treatment for ureteric stones 
cannot be conclusively refuted. Particularly in patients with distal stones over 5mm, 
there is sufficient evidence to support the continued use of medical expulsive therapy 
with α-blockers. 
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Table 1: Included Study Characteristics 
Study Year Treatment 
Number  
Randomised 
Number  
Analysed 
Mean 
Age 
(years) 
Mean 
Stone 
Size 
(mm) 
Stone Expulsion 
Rate (%) 
Stone Expulsion 
Time (mean 
days) 
Risk of Bias 
Score 
Abdel-Meguid[11]  2010 
Tamsulosin 0.4mg vs. 
Placebo 
167 
Tamsulosin: 75 
Placebo: 75 
35 5.5 
Tamsulosin: 81.3 
Placebo: 56.0 
 - Low 
 26 
Agrawal[20] 2009 
Tamsulosin 0.4mg vs. 
Alfuzosin 10mg vs. 
Placebo 
102 
Tamsulosin: 34 
Alfuzosin: 34 
Placebo: 34 
35.1 6.4 
Tamsulosin: 82.3 
Alfuzosin: 70.5 
Placebo: 35.2 
Tamsulosin: 12.3 
Alfuzosin: 14.5 
Placebo: 24.5 
Intermediate 
Ahmad[21] 2015 
Tamsulosin 0.4mg vs. 
Placebo 
100 
Tamsulosin: 50 
Placebo: 50 
36.3 5.8 
Tamsulosin: 85.7 
Placebo: 54.2 
- Intermediate 
Ahmed[59] 2010 
Tamsulosin 0.4mg vs. 
Alfuzosin 10mg vs. 
Control 
90 
Tamsulosin: 29 
Alfuzosin: 30 
Control: 28 
40.2 5.3 
Tamsulosin: 86.2 
Alfuzosin: 76.7 
Control: 50.0 
Tamsulosin: 7.5 
Alfuzosin: 8.3 
Control: 13.9 
Intermediate 
Al-Ansari[12] 2010 
Tamsulosin 0.4mg vs. 
Placebo 
100 
Tamsulosin: 50 
Placebo: 46 
36.7 5.96 
Tamsulosin: 82.0 
Placebo: 61.0 
Tamsulosin: 6.4 
Placebo: 9.9 
Low 
Albert[60] 2016 
Tamsulosin 0.4mg vs. 
Silodosin 8mg vs. 
Control 
120 
Tamsulosin: 40 
Silodosin: 40 
Control: 40 
33.7 6.9 
Tamsulosin: 80.0 
Silodosin: 85.0 
Control: 37.5 
Tamsulosin: 12.0 
Silodosin: 12.0 
Control: 20.0 
Intermediate 
Aldemir[22] 2011 
Tamsulosin 0.4mg vs. 
Rowatinex 10mg vs. 
Control 
90 
Tamsulosin: 31 
Rowatinex: 30 
Control: 29 
44.1 6.7 
Tamsulosin: 80.6 
Rowatinex: 43.3 
Control: 37.9 
Tamsulosin: 3.5 
Rowatinex: 6.0 
Control: 7.0 
Intermediate 
Alizadeh[61]  2014 
Tamsulosin 0.4mg vs. 
Control 
102 
Tamsulosin: 50 
Control: 46 
- 4.7 
Tamsulosin: 82.0 
Control: 62.5 
Tamsulosin: 3.7 
Control: 4.7 
High 
Arrabal-
Martin[23] 
2010 
Tamsulosin 0.4mg vs 
Control 
70 
Tamsulosin: 35 
Control: 35 
- - 
Tamsulosin: 85.7 
Control: 54.3 
Tamsulosin: 8.0 
Control: 13.8 
Intermediate 
Autorino[62]  2005 
Tamsulosin 0.4mg vs. 
Control 
64 
Tamsulosin: 32 
Control: 32 
44.0 6.1 
Tamsulosin: 88.0 
Control: 60.0 
Tamsulosin: 4.8 
Control: 7.4 
High 
Avdoshin 2005 
Tamsulosin 0.4mg vs. 
Control 
87 
Tamsulosin: 42 
Control: 45 
- 7.4 
Tamsulosin: 74.0 
Control: 24.0 
- High 
Ayubov[24]* 2007 
Doxazosin 4mg vs. 
Control 
61 
Doxazosin:30  
Control: 31 
- - 
Doxazosin: 93.3 
Control: 60.9 
- Intermediate 
Balci[25]  2014 
Tamsulosin 0.4mg vs. 
Nifedipine 10mg vs. 
Control 
75 
Tamsulosin: 25 
Nifedipine: 25 
Control: 25 
36.8 6.6 
Tamsulosin: 76.0 
Nifedipine: 64.0 
Control: 36.0 
Tamsulosin: 9.0 
Nifedipine: 9.1 
Control: 10.3 
Intermediate 
Bhat[64] 2015 
 
Alfuzosin 10mg vs. 
Placebo 
92 
Alfuzosin: 46  
Placebo: 46 
- - 
Alfuzosin: 89.1 
Placebo: 47.8 
- High 
Červenàkov[26]  2002 
Tamsulosin 0.4mg vs. 
Control 
104 
Tamsulosin: 51 
Control: 51 
47.0 - 
Tamsulosin: 80.4 
Control: 62.8 
- Intermediate 
Cha[27] 2012 
Tamsulosin 0.2mg vs. 
Tamsulosin 0.4mg vs. 
Alfuzosin 10mg vs. 
Control 
141 
Tamsulosin 0.2mg: 41 
Tamsulosin 0.4mg : 30 
Alfuzosin: 36 
Control: 34 
44.1 5.7 
Tamsulosin 
0.2mg: 78.0 
Tamsulosin 
0.4mg : 76.7 
Alfuzosin: 75.0 
Control: 47.1 
Tamsulosin 
0.2mg: 8.5 
Tamsulosin 
0.4mg : 7.8 
Alfuzosin: 8.2 
Control: 13.6 
Intermediate 
Chau[28] 2011 
Alfuzosin 10mg vs. 
Control 
79 
Alfuzosin: 33 
Control: 34 
47.7 6.8 
Alfuzosin: 81.8 
Control: 50.0 
Alfuzosin: 7.1 
Control: 8.0 
Intermediate 
De Sio[29] 2006 
Tamsulosin 0.4mg vs. 
Control 
96 
Tamsulosin: 50 
Control: 46 
45.4 6.7 
Tamsulosin: 90.0 
Control: 58.7 
Tamsulosin: 4.4 
Control: 7.5 
Intermediate 
Doluoglu[30] 2015 
Tamsulosin 0.4mg vs. 
Sexual Intercourse 
vs. Control 
75 
Tamsulosin: 21 
Intercourse: 31 
Control: 23 
36.1 4.9 
Tamsulosin: 81.0 
Intercourse: 93.5 
Control: 78.3 
Tamsulosin: 16.6 
Intercourse:10.0 
Control: 18.0 
Intermediate 
Dong[31] 2009 
Tamsulosin 0.2mg vs 
Control  
40 
Tamsulosin: 19 
Control: 21 
49.6 4.9 
Tamsulosin: 47.4 
Control: 38.1 
- Intermediate 
El Said[65] 2015 
Alfuzosin 10mg vs 
Control 
54 
Alfuzosin: 28 
Control: 26 
32.5 6.1 
Alfuzosin: 53.6 
Control: 26.9 
Alfuzosin: 9.0 
Control: 19.0 
High 
 27 
El-Gamal[32]  2012 
Tamsulosin 0.4mg vs. 
Potassium Citrate vs. 
Tamsulosin 0.4mg 
and Potassium 
Citrate vs. Placebo 
191 
Tamsulosin: 48 
PC: 46 
Tamsulosin + PC: 46  
Placebo: 46 
36.5 7.8 
Tamsulosin: 68.8 
PC: 46.0 
Tamsulosin + PC: 
85.0  
Placebo: 46.0 
- Intermediate 
Erturhan[33]  2007 
Tamsulosin 0.4mg vs. 
Tamsulosin 0.4mg + 
Tolterodine 2mg vs. 
Tolterodine 2mg vs. 
Control 
120 
Tamsulosin: 29 
Tamsulosin and 
Tolterodine: 30 
Tolterodine: 28 
Placebo: 28 
31.5 7.0 
Tamsulosin: 73.3 
Tamsulosin and 
Tolt: 70.0 
Tolterodine: 
46.6 
Placebo: 40.0 
Tamsulosin: 6.4 
Tamsulosin and 
Tolt: 7.5 
Tolterodine: 
11.4 
Placebo: 12.0 
Intermediate 
Eryildirim[66]  2015 
Tamsulosin 0.4mg vs. 
Control 
120 
Tamsulosin: 60 
Control: 60 
37.2 - 
Tamsulosin: 43.0 
Control: 36.6 
- High 
Ferre[34]  2008 
Tamsulosin 0.4mg vs. 
Control 
80 
Tamsulosin: 35 
Control: 37 
46 3.65 
Tamsulosin: 71.1 
Control: 61.5 
Tamsulosin: 1.0 
Control: 3.0 
Intermediate 
Furyk[13] 2016 
Tamsulosin 0.4mg vs. 
Placebo 
403 
Tamsulosin: 161 
Placebo: 155 
- - 
Tamsulosin: 87.0 
Placebo: 81.9 
- Low 
Georgescu[35] 2014 
Tamsulosin 0.4mg vs. 
Silodosin 8mg vs. 
Control 
150 
Tamsulosin: 50 
Silodosin: 50 
Control: 50 
44.3 5.17 
Tamsulosin: 76.0 
Silodosin: 82.0 
Control: 50.0 
Tamsulosin: 9.0 
Silodosin: 7.8 
Control: 12.0 
Intermediate 
Griwan[67] 2010 
Tamsulosin 0.4mg vs. 
Control 
60 
Tamsulosin: 30 
Control: 30 
35.1 6.3 
Tamsulosin: 90.0 
Control: 70.0 
- High 
Hermanns[14]  2009 
Tamsulosin 0.4mg vs. 
Placebo 
100 
Tamsulosin: 45 
Placebo: 45 
38.5 3.9 
Tamsulosin: 86.7 
Placebo: 88.9 
Tamsulosin: 7.0 
Placebo: 10.0 
Low 
Ibrahim[36] 2013 
Tamsulosin 0.4mg vs. 
Alfuzosin 10mg vs. 
Control 
112 
Tamsulosin: 40 
Alfuzosin: 40 Control: 
32 
44.3 5.7 
Tamsulosin: 76.0 
Alfuzosin: 82.0 
Control: 26.0 
Tamsulosin: 9.0 
Alfuzosin:7.8 
 Control: 12.0 
Intermediate 
Islam[37] 2010 
Tamsulosin 0.4mg vs. 
Nifedipine vs. 
Control 
91 
Tamsulosin: 32 
Nifedipine: 31 
Control: 28 
45.6 5.9 
Tamsulosin: 84.8 
Nifedipine: 71.0 
Control: 46.4 
Tamsulosin: 7.9 
Nifedipine: 9.3 
Control: 12.8 
Intermediate 
Itoh[38] 2013 
Silodosin 8mg vs. 
Control 
112 
Silodosin: 55 
Control 56 
56.1 - 
Silodosin: 72.7 
Control: 55.4 
Silodosin: 9.29 
Control: 13.4 
Intermediate 
Itoh[39] 2011 
Silodosin 8mg vs. 
Control 
187 
Silodosin: 89 
Control 92 
56.9 5.7 
Silodosin: 66.3 
Control: 50.0 
Silodosin: 10.3 
Control: 15.2 
Intermediate 
Kaneko[40] 2010 
Tamsulosin 0.2mg vs. 
Control 
71 
Tamsulosin: 31 
Control: 34 
47.5 4.7 
Tamsulosin: 77.4 
Control: 50.0 
Tamsulosin: 15.0 
Control: 17.0 
Intermediate 
Kim[41] 2007 
Tamsulosin 0.2mg vs. 
control 
76 
Tamsulosin: 34 
Control: 42 
43.2 5.0 
Tamsulosin: 76.5 
Control: 42.9 
- Intermediate 
Kumar[68] 2013 
Tamsulosin 0.4mg vs. 
Naftopidil 75mg vs. 
Control 
120 
Tamsulosin: 40 
Naftopidil: 40 
Control: 40 
33.3 6.9 
Tamsulosin: 40.0 
Naftopidil: 40.0 
Control: 40.0 
Tamsulosin: 8.7 
Naftopidil: 9.1 
Control: 14.0 
High 
Küpeli[42] 2004 
Tamsulosin 0.4mg vs. 
Control 
30 
Tamsulosin: 15 
Control: 15 
42.9 4.8 
Tamsulosin: 53.0 
Control: 20.0 
- Intermediate 
Laddha[69]* 2015 
Tamsulosin 0.4mg vs. 
Placebo vs. Tadalafil 
150 
Tamsulosin: 50 
Placebo: 50 
- - 
Tamsulosin: 74.0 
Placebo: 58.0 
- High 
Lee[43] 2014 
Tamsulosin 0.2mg vs. 
Control 
108 
Tamsulosin: 54 
Control: 54 
45.8 - 
Tamsulosin: 74.1 
Control: 46.3 
Tamsulosin: 14.3 
Control: 19.6 
Intermediate 
Liatsikos[70] 2007 
Doxasosin 4mg vs. 
Control 
73 
Doxasosin: 42 
Control: 32 
46.2 5.4 
Doxasosin: 78.6 
Control: 51.6 
Doxasosin: 7.3 
Control: 10.5 
High 
Lojanapiwat[71]  2008 
Tamsulosin 0.2mg vs. 
Tamsulosin 0.4mg vs. 
Control 
75 
Tamsulosin 0.2mg: 25 
Tamsulosin 0.4mg : 25 
Control: 25 
47.1 6.5 
Tamsulosin 
0.2mg: 40.0 
Tamsulosin 
0.4mg : 68.0 
Control: 4.0 
Tamsulosin 
0.2mg: 9.3 
Tamsulosin 
0.4mg : 10.7 
Control: 23.0 
High 
Maitra[44] 2012 
Tamsulosin 0.4mg vs. 
Nifedipine + 
Tamsulosin 0.4mg vs. 
Placebo 
150 
Tamsulosin: 50 
Tamsulosin + 
Nifedipine: 50 
Placebo: 50 
36.1 6.5 
Tamsulosin: 74.0 
Tamsulosin + 
Nifedipine: 86.0 
Placebo: 30.0 
Tamsulosin: 28.5 
Tamsulosin + 
Nifedipine: 20.5 
Placebo: 37.7 
Intermediate 
Mohseni[45] 2006 
Terazosin 10mg vs. 
Control 
64 
Terazosin: 32 
Control: 32 
41.7 6.8 
Terazosin: 90.6 
Control: 62.5 
Terazosin: 3.2 
Control: 6.0 
Intermediate 
Mukhtarov[46]* 2007 
Doxazosin 4mg vs. 
Control 
52 
Doxazosin: 27 
Control: 25 
- 4.1 
Doxazosin: 88.9 
Control: 72 
Doxazosin: 6.4 
Control: 8.8 
Intermediate 
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Ochoa-Gomez[47] 2011 
Tamsulosin 0.4mg vs. 
Placebo 
71 
Tamsulosin: 32 
Placebo: 33 
38.4 5.3 
Tamsulosin: 68.8 
Placebo: 69.7 
Tamsulosin: 22 
Placebo: 23 
Intermediate 
Pedro[15] 2008 
Alfuzosin ? vs. 
Placebo 
69 
Alfuzosin: 34 
Placebo: 35 
39.4 4.0 
Alfuzosin: 73.5 
Placebo: 77.1 
Alfuzosin: 5.3 
Placebo: 8.5 
Low 
Pickard[16] 2015 
Tamsulosin 0.4mg vs. 
Nifedipine 30mg vs. 
Placebo 
1167 
Tamsulosin: 378 
Nifedipine: 379 
Placebo: 379 
42.7 4.5 
Tamsulosin: 81.2 
Nifedipine: 80.2 
Placebo: 79.9 
Tamsulosin: 16.5 
Nifedipine: 16.2 
Placebo: 15.9 
Low 
Porpiglia[48] 2006 
Tamsulosin 0.4mg 
vs.Tamsulosin 0.4mg 
+ Deflazocort vs. 
Deflazocort vs 
Control 
114 
Tamsulosin: 33 
Tamsulosin + Def: 33 
Def: 24 
Control: 24 
46.6 5.9 
Tamsulosin: 60.0 
Tamsulosin + 
Def: 84.8 
Def: 37.5 
Control: 33.3 
- Intermediate 
Ramesh[72] 2015 
Tamsulosin 0.4mg vs. 
Tamsulosin + 
Deflazacort vs. 
Control 
90 
Tamsulosin: 31 
Tamsulosin + 
Deflazacort: 26  
Control: 34  
- - 
Tamsulosin: 38.7 
Tamsulosin + 
Deflazacort: 50.0  
Control: 32.4 
- HIgh 
Rathi[49]* 2014 
Tamsulosin 0.4mg vs. 
Silodosin 8mg vs. 
Control 
87 
Tamsulosin: 30 
Silodosin: 29 
Control: 28 
- - 
Tamsulosin: 76.7 
Silodosin: 86.2 
Control: 50.0 
- Intermediate 
Reddy[50] 2016 
Tamsulosin 0.4mg vs. 
Alfuzosin 10mg vs. 
Placebo 
150 
Tamsulosin: 50 
Alfuzosin: 75 
Placebo: 50 
26.4 6.7 
Tamsulosin: 72 
Alfuzosin: 74 
Placebo: 32 
Tamsulosin: 7.6 
Alfuzosin: 8.6 
 Placebo: 8.6 
Intermediate 
Resim[51] 2005 
Tamsulosin 0.4mg vs. 
Control 
60 
Tamsulosin: 30 
Control: 30 
34.4 7.8 
Tamsulosin: 86.6 
Control: 73.3 
- Intermediate 
Sameer[17] 2014 
Nifedipine 30mg vs. 
Alfuzosin 10mg vs. 
Control 
105 
Nifedipine: 35 
Alfuzosin: 35 
Control: 35 
32.2 6.38 
Nifedipine: 60.0 
Alfuzosin: 85.7 
Control: 20.0 
Nifedipine: 12.6 
Alfuzosin: 12.0 
Control: 12.3 
Low 
Sayed[52] 2008 
Tamsulosin 0.4mg vs. 
Control 
90 
Tamsulosin: 45 
Control: 45 
38.2 6.6 
Tamsulosin: 88.9 
Control: 51.1 
Tamsulosin: 7.3 
Control: 12.5 
Intermediate 
Su[73] 2016 
Tamsulosin 0.4mg vs. 
Silodosin 8mg vs. 
Placebo 
204 
Tamsulosin: 67 
Silodosin: 68 
Placebo: 69 
51.5 6.6 
Tamsulosin: 85.1 
Silodosin: 79.2 
Placebo: 59.2 
Tamsulosin: 6.3 
Silodosin: 6.0 
Placebo: 9.8 
High 
Sümer[74]  2012 
Alfuzosin 10mg vs. 
Prednisolone 16mg 
vs. Control 
30 
Alfuzosin: 10 
Prednisolone: 10 
Control: 10 
38.0 - 
Alfuzosin: 40.0 
Prednisolone: 
0.0 
Control: 0.0 
- High 
Sun[79] 2009 
Naftopidil 50mg vs. 
Control 
60 
Naftopidil: 30 
Control: 30 
38.0 5.6 
Naftopidil: 90.0 
Control: 26.7 
Naftopidil: 7.0 
Control: 6.0 
HIgh 
Sur[18] 2015 
Silodosin 8mg vs. 
Placebo 
246 
Silodosin: 119 
Placebo: 120 
47.0 - 
Silodosin: 52.0 
Placebo: 44.0 
- Low 
Taghavi[53]* 2005 
Tamsulosin 0.4mg vs. 
Nifedipine 20mg vs. 
Control 
64 
Tamsulosin: 20 
Nifedipine: 20 
Control: 24 
38.0 - 
Tamsulosin: 90.0 
Nifedipine: 75.0 
Control: 45.83 
Tamsulosin: 8.2 
Nifedipine: 10.0 
Control: 14.2 
Intermediate 
Thapa[54] 2014 
Tamsulosin 0.4mg vs. 
Control 
70 
Tamsulosin: 35 
Control: 35 
31.5 6.3 
Tamsulosin: 80.0 
Control: 62.9 
- Intermediate 
Ukhal[55]* 1999 
Doxazosin 2mg vs. 
Control 
65 
Doxazosin: 35 
Control: 30 
- 7.1 
Doxazosin: 74.3 
Control: 47.0 
- Intermediate 
Vincendeau[19] 2010 
Tamsulosin 0.4mg vs. 
Placebo 
129 
Tamsulosin: 61 
Placebo: 61 
38.9 3.1 
Tamsulosin: 77 
Placebo: 70.5 
Tamsulosin: 9.6 
Placebo: 10.1 
Low 
Wang[76] 2008 
Tamsulosin 0.4mg vs. 
Terazosin 2mg vs. 
Control 
95 
Tamsulosin: 32 
Terazosin: 32 
Control: 31 
50.9 - 
Tamsulosin: 81 
Terazosin: 78 
Control: 55 
Tamsulosin: 6.3 
Terazosin: 6.3 
Control: 10.1 
High 
Yencilek[56] 2010 
Tamsulosin 0.4mg vs. 
Control 
92 
Tamsulosin: 42 
Control: 50 
34.2 6.5 
Tamsulosin: 35.7 
Control: 30 
Tamsulosin: 8.4 
Control: 11.6 
Intermediate 
Yilmaz[57] 2005 
Tamsulosin 0.4mg vs. 
Terazosin 5mg vs. 
Doxazosin 4mg vs. 
Control 
114 
Tamsulosin: 29 
Terazosin: 28 
Doxazosin: 29 
Control: 28 
41.5 6.0 
Tamsulosin: 79.3 
Terazosin: 78.6 
Doxazosin: 75.9 
Control: 53.6 
Tamsulosin: 6.3 
Terazosin: 5.8 
Doxazosin: 5.9 
Control: 10.5 
Intermediate 
Yuksel[58] 2015 
Silodosin 4mg vs. 
Control 
70 
Silodosin:35 
Control: 35 
35.3 6.4 
Silodosin: 91.4 
Control: 71.4 
Silodosin: 8.0 
Control: 12.9 
Intermediate 
Zehri[77] 2010 
Doxazosin 2mg vs. 
Control 
66 
Doxazosin: 33 
Control: 32 
33.1 5.39 
Doxazosin: 69.7 
Control: 37.5 
Doxazosin: 7.0 
Control: 12.5 
High 
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